On August 19, 2026, a Michigan appellate court revived a $900,000 coverage dispute that is sending shockwaves through brain injury litigation nationwide. Corewell Health v. State Farm places hyperbaric oxygen therapy insurance coverage denial TBI squarely at the center of a battle between insurers armed with federal clinical guidelines and providers armed with unpaid bills running into six figures. If you or a loved one sustained a traumatic brain injury and your insurer denied HBOT, this case — and the legal strategies it validates — matters enormously to the value of your claim.
Corewell Health v. State Farm: What the 2026 Michigan Appellate Decision Actually Means
The Michigan Court of Appeals revived the Corewell Health v. State Farm lawsuit on August 19, 2026, reinstating a claim worth approximately $900,000 in disputed hyperbaric oxygen therapy charges. The lower court had dismissed the suit, but the appellate panel found that questions of medical necessity and contractual coverage could not be resolved at the pleadings stage — meaning the case must proceed to discovery and potentially trial. That procedural posture is significant: it signals that Michigan courts are unwilling to let insurers escape HBOT liability disputes through early dismissal motions alone.
For brain injury claimants, the takeaway is structural. When a hospital system the size of Corewell Health — one of Michigan’s largest integrated health networks — cannot get payment for delivered HBOT services, individual patients face the same denial wall but with far fewer litigation resources. The appellate reversal creates a roadmap: challenge the denial, force discovery on the insurer’s internal coverage criteria, and present evidence that the treatment was medically necessary for that specific patient’s injury profile. TBI litigation in Michigan is entering a new phase in 2026, and hyperbaric oxygen therapy insurance coverage denial TBI disputes are at its leading edge.
The $900,000 figure is not incidental. It reflects a realistic picture of HBOT costs at scale — typically $250 to $450 per session with treatment protocols ranging from 20 to 80 sessions for TBI patients. Multiply that across a hospitalized patient with severe or moderate TBI and you approach or exceed the Corewell figure quickly. For individual claimants pursuing personal injury settlements, understanding how these costs are calculated is essential, and using a personal injury settlement calculator can help you begin to quantify what an HBOT denial could mean to your overall damages picture.
The Clinical Evidence Problem: Why VA/DOD Guidelines Create Both Shields and Swords
The central evidentiary tension in every hyperbaric oxygen therapy insurance coverage denial TBI case is a split within the medical establishment itself. The VA/DOD Clinical Practice Guideline, most recently updated and controlling in 2026 proceedings, explicitly recommends against HBOT for mild traumatic brain injury. The basis for that recommendation is methodologically rigorous: four of five military randomized controlled trials found that HBOT performed no better than sham treatment — pressurized air without elevated oxygen — in reducing post-concussion symptoms.
Insurers have seized on this guidance as a blanket justification for denial. The problem is that the VA/DOD guideline is specifically scoped to mild TBI, predominantly in a military population experiencing persistent post-concussion syndrome. It says relatively little about moderate-to-severe TBI, pediatric TBI, or the acute hospitalized patient — precisely the populations that generate the largest HBOT bills and the most contested denials. The evidence profile for those subgroups is meaningfully different, and courts in 2026 are beginning to recognize that insurers who cite VA/DOD guidance for all TBI cases are overreaching the guideline’s own stated scope.
The table below summarizes the current state of clinical evidence stratified by TBI severity and population, which is the framework litigators should use when countering blanket denials.
| TBI Category | VA/DOD HBOT Recommendation | Key Evidence Basis | Litigation Posture |
|---|---|---|---|
| Mild TBI / Concussion (Military) | Recommends Against | 4 of 5 RCTs: HBOT = Sham (VA/DOD CPG 2021) | Insurer-favorable; difficult to overcome |
| Mild TBI / Concussion (Civilian) | No specific recommendation | Limited civilian-population RCT data | Contested; fact-intensive inquiry |
| Moderate-to-Severe TBI | Not addressed by VA/DOD guideline | Case series; emerging trial data | Claimant-favorable; guideline gap |
| Pediatric TBI | Not addressed by VA/DOD guideline | Distinct physiology; separate evidence base | Claimant-favorable; scope argument |
| Acute Hospitalized TBI | Not addressed by VA/DOD guideline | Institutional protocol-driven | Claimant-favorable; necessity argument |
For TBI cases arising from motor vehicle collisions — where injury severity often exceeds the mild classification — the guideline gap is particularly exploitable. A passenger who sustains a moderate TBI in a highway collision and receives HBOT during acute hospitalization occupies a category the VA/DOD guideline was never designed to address. If that collision involved a commercial vehicle, the damages stakes rise further, and a truck accident calculator can help establish the baseline economic losses against which HBOT denial costs should be added.
Appellate Reversal Strategies: How Corewell Changes the Litigation Playbook
The Corewell Health v. State Farm reversal is not just a procedural victory — it encodes several tactical lessons for attorneys litigating hyperbaric oxygen therapy insurance coverage denial TBI cases in 2026. Understanding why the appellate court reversed helps claimants and counsel structure their own challenges more effectively.
Challenging the Internal Coverage Criteria
Michigan’s No-Fault Act and comparable insurance statutes in most states require that coverage denials be based on objective, documented medical necessity determinations — not generic clinical guidelines applied without individualized review. In Corewell, a central issue is whether State Farm applied an individualized medical necessity analysis or simply imported VA/DOD guidance wholesale. Discovery into an insurer’s internal utilization review protocols, the credentials of the reviewing physician, and whether that reviewer examined the actual patient records is now squarely supported by the appellate decision as an appropriate line of inquiry.
Scope Argument: Forcing the Insurer to Own the Guideline’s Limitations
Effective appellate reversal strategy in hyperbaric oxygen therapy insurance coverage denial TBI cases increasingly focuses on making the insurer defend the breadth of its reliance. If your insurer cited VA/DOD guidance, depose their medical director on the guideline’s stated scope. Get them on record stating that the guideline applies to moderate TBI, to pediatric patients, or to acute hospitalization contexts — positions the guideline’s own authors do not take. This deposition strategy, validated by the Corewell litigation, converts the insurer’s strongest evidence into a liability.
Eye-Tracking as Objective Causation and Severity Evidence
One of the most important evidentiary developments supporting HBOT coverage litigation in 2026 is the widespread adoption of FDA-cleared eye-tracking oculomotor assessment technology, backed by approximately 15 years of peer-reviewed research. Unlike traditional concussion evaluations that rely heavily on subjective symptom reporting, oculomotor assessment produces quantifiable, reproducible data on brain function. In insurance disputes, this matters in two ways: it establishes objective causation linking the injury to the accident, and it provides a measurable severity baseline that supports the medical necessity of intensive interventions like HBOT. Insurers cannot credibly dismiss oculomotor data as malingering or exaggeration the way they can attack symptom diaries. Courts and arbitrators in 2026 are increasingly receptive to this evidence as a cornerstone of TBI coverage disputes.
Analogizing to Therapeutic Hypothermia Precedents
A parallel line of cases in 2026 involves neonatal cooling therapy — therapeutic hypothermia for hypoxic-ischemic encephalopathy — which has demonstrated a 25% reduction in death or severe disability when initiated within a strict six-hour window. Insurers who denied or delayed cooling therapy coverage have faced significant liability in coverage and malpractice litigation. HBOT attorneys are now drawing explicit analogies: both therapies involve time-sensitive, mechanistically plausible neurological interventions that insurers initially resisted on evidence grounds. The hypothermia precedent establishes that courts will not defer indefinitely to insurer conservatism when treatment has physiological rationale and a documented population of beneficiaries, even when the evidence base is still developing for some subgroups. Courts applying medical necessity legal standards are finding this analogy increasingly persuasive.
Calculating Damages When HBOT Is Provided Despite Denial
When a brain injury patient receives hyperbaric oxygen therapy after the insurer has denied coverage, the resulting economic landscape is complex but highly calculable — and that calculation is central to both individual litigation and the systemic dispute illustrated by Corewell. Attorneys handling hyperbaric oxygen therapy insurance coverage denial TBI cases in 2026 must address damages across several distinct categories.
Direct Medical Cost Recovery
The most straightforward damage category is the billed HBOT cost itself. At $250 to $450 per session, a 40-session protocol — common for moderate-to-severe TBI — generates $10,000 to $18,000 in treatment costs alone. Hospitalized patients receiving HBOT as part of a comprehensive acute care protocol may face facility charges that push individual case costs well above $100,000. The Corewell litigation’s $900,000 figure reflects aggregated institutional billing across multiple patients. For individual claimants, the operative question is whether the denied charges become recoverable as economic damages in a personal injury action against the at-fault party, a first-party insurance bad faith action against the carrier, or both.
Consequential Damages from Delayed or Foregone Treatment
A more complex — and often larger — damage category involves the downstream consequences of an HBOT denial. If a patient cannot afford out-of-pocket treatment and foregoes HBOT as a result of the denial, any worsening of neurological outcome attributable to that gap may be recoverable as consequential damages. Establishing this causal chain requires neurological expert testimony linking the denial to the outcome, which is precisely why objective evidence like oculomotor assessment data — establishing baseline severity at the time of denial — becomes critical. Michigan law, following the No-Fault Act framework at issue in Corewell, supports recovery of medical expenses that are reasonably necessary, and the Michigan Department of Insurance and Financial Services provides regulatory guidance on what coverage standards apply.
Bad Faith and Extracontractual Damages
Where an insurer denies HBOT coverage without conducting an individualized review, relying on an inapplicable guideline, or otherwise violating its duty of good faith, extracontractual damages become available in most jurisdictions. These can include attorney fees, consequential economic losses, and in egregious cases, punitive damages. The Corewell appellate reversal, by permitting full discovery into State Farm’s denial process, opens the door to exactly this kind of bad faith exposure. Claimants in car accident TBI cases should understand that HBOT denial damages may substantially exceed the treatment cost itself when bad faith is provable, and a car accident settlement calculator can help establish the full economic picture before litigation strategy is set.
Structured Expert Testimony for Settlement Leverage
In 2026, the most effective damage calculation packages in HBOT denial cases combine four expert inputs: a neurologist or neurosurgeon establishing injury severity and treatment necessity; an oculomotor assessment specialist providing objective functional data; a life care planner projecting future medical needs based on the current neurological status; and an economist calculating present value of future losses. This four-expert structure transforms what insurers characterize as speculative HBOT costs into a documented, juror-accessible economic narrative. Settlement values in cases with this evidentiary foundation are substantially higher than in cases relying solely on medical records and billing statements. The CDC’s TBI resource center provides epidemiological context on long-term TBI outcomes that life care planners routinely incorporate into these calculations.
Frequently Asked Questions About HBOT Coverage Denial in TBI Cases
Can my insurer legally deny HBOT coverage for TBI by citing VA/DOD guidelines?
An insurer can cite VA/DOD guidelines as part of a medical necessity determination, but the legality of the denial depends on whether that guideline actually applies to your specific injury profile. The VA/DOD Clinical Practice Guideline recommends against HBOT specifically for mild TBI in a military population. If you sustained moderate-to-severe TBI, are a pediatric patient, or are a civilian, the guideline’s scope may not cover your situation. Courts, including the Michigan appellate court in the 2026 Corewell Health v. State Farm decision, are scrutinizing whether insurers apply these guidelines with appropriate individualization. A blanket denial that ignores your specific clinical circumstances may constitute a bad faith coverage practice.
What is the significance of the Corewell Health v. State Farm 2026 decision for individual TBI claimants?
The August 19, 2026 appellate reversal in Corewell Health v. State Farm is significant for individual claimants in two ways. First, it establishes that Michigan courts will allow hyperbaric oxygen therapy insurance coverage denial TBI cases to proceed past early dismissal motions, which means insurers cannot escape litigation through procedural shortcuts. Second, it opens discovery into how insurers make HBOT denial decisions — including the credentials of reviewing physicians and whether individualized analysis occurred. Even if you are not in Michigan, this decision reflects a broader appellate trend that your attorney can cite in briefing coverage disputes in other jurisdictions.
How does eye-tracking oculomotor assessment strengthen an HBOT coverage denial claim?
FDA-cleared eye-tracking oculomotor assessment, supported by approximately 15 years of peer-reviewed research, produces objective, quantifiable data about brain function that insurers cannot easily dismiss as subjective or exaggerated. In an HBOT coverage denial dispute, this technology serves two critical functions: it establishes objective evidence of TBI severity at the time of treatment (supporting medical necessity), and it provides a measurable neurological baseline that can be compared against post-treatment assessments to document improvement or deterioration. This objective evidence is particularly valuable when insurers argue that HBOT was not necessary because the injury was only mild or that symptoms were not objectively verifiable. Courts and arbitrators in 2026 are increasingly treating oculomotor data as foundational evidence in TBI insurance disputes.
What damages can I recover if my insurer denied HBOT and I paid out of pocket or went without treatment?
If you paid out of pocket for HBOT after an insurer denial, you may recover those costs as economic damages in a personal injury action against the at-fault party or in a bad faith insurance claim against your insurer. If you foregone treatment because of the denial and your neurological condition worsened as a result, consequential damages — including future medical costs, lost earning capacity, and pain and suffering — may be recoverable, provided expert testimony can establish the causal link between the denial and the outcome. Where the insurer’s denial process was deficient — relying on inapplicable guidelines, failing to conduct individualized review, or misrepresenting coverage terms — extracontractual damages including attorney fees and potentially punitive damages may also be available depending on your state’s insurance bad faith law.
Are pediatric TBI cases treated differently in HBOT coverage disputes?
Yes, and significantly so. The VA/DOD guideline that recommends against HBOT for mild TBI was developed based on military adult populations and does not address pediatric TBI at all. Pediatric brain injury involves distinct developmental physiology, different recovery trajectories, and a separate emerging evidence base. Insurers who deny HBOT in pediatric TBI cases by citing VA/DOD guidance are applying a guideline outside its stated population scope, which is a strong argument for reversal in coverage litigation. Additionally, the emerging 2026 litigation around neonatal cooling therapy for hypoxic-ischemic encephalopathy demonstrates that courts are applying heightened scrutiny to insurer denials of neurological interventions in pediatric and neonatal patients, creating favorable precedent that pediatric HBOT attorneys are actively leveraging.
Legal disclaimer: This article is provided for informational and educational purposes only and does not constitute legal advice or create an attorney-client relationship; consult a licensed attorney in your jurisdiction regarding your specific legal situation.
Related reading: Insurance Claim Denial Appeal: State Regulatory Process Vs. Bad Faith Litigation (2026)
Related reading: Protecting A Legitimate Car Accident Claim When Insurers Suspect Fraud: 2026 Proof & Evidence Strategy
Robert Callahan is a TBI and Catastrophic Injury Researcher with extensive knowledge of personal injury law and settlement values across the United States. With years of experience analyzing brain injury / tbi claims only cases, Robert helps injury victims understand their legal rights and the potential value of their claims. Robert is not an attorney and the information provided is for educational purposes only.